Boston Medical Center Corporation

Boston Medical Center Corporation, doing business as BMC, a tax-exempt academic medical center and safety-net hospital based in Boston, operates as a prime recipient and contractor on federal health research and clinical services awards, with no SBA set-asides across its footprint. BMC is a nonprofit hospital organization headquartered at 1 Boston Medical Center Place, Roxbury, Massachusetts, functioning as a parent entity with direct federal award responsibility across 825 awards spanning contracts, grants, and cooperative agreements.

BMC's federal activity concentrates heavily on biomedical research and clinical trial support. The organization holds a $86.008 million indefinite-delivery multiple-award contract from the Centers for Disease Control and Prevention Pittsburgh for Clinical Immunization Safety Assessment (CISA) services, with base performance through September 2028 and nine active task orders totaling $4.3 million in potential value. Recent prime contract work includes a $803,870 cost-no-fee delivery order awarded September 2026 from CDC Pittsburgh for the HOME LAIV Study supporting Executive Order 14398, a $1.271 million fixed-price contract awarded February 2026 with Veterans Integrated Service Network 1 for ophthalmology physician services through January 2036, and a $719,095 cost-no-fee delivery order from the National Institute of Child Health and Human Development for a Phase 2b contraceptive efficacy and safety study. BMC also holds a $944,048 definitive contract with VISN 1 for education cost sharing in Jamaica Plain, Massachusetts, running through June 2030.

Across 141 National Institutes of Health awards, BMC functions as a prime grant recipient supporting a diverse biomedical research portfolio. Recent grants include a $3.517 million award from the National Institute of Diabetes and Digestive and Kidney Diseases for induced pluripotent stem cell-derived endothelial cell therapy for liver disease (CFDA 93.847), an $870,407 grant from the National Institute on Drug Abuse for the PRIME Years study on Medicaid effects on youth substance use post-incarceration (CFDA 93.279), an $888,383 grant from NIDDK for dietary potassium and gene-environment interactions in apolipoprotein L1 nephropathy research (CFDA 93.847), and a $2.67 million grant from NIDA for the LINK intervention using informatics to reduce opioid overdose and HIV infection (CFDA 93.279). BMC received a $1.397 million cooperative agreement from the Centers for Disease Control and Prevention in September 2025 under the Injury Prevention and Control Research program (CFDA 93.136) for the SafeSpot Hotline engaging overdose survivors in secondary overdose prevention, and a $500,214 grant from the National Institute for Minority Health and Health Disparities in September 2025 for clinic-based health IT tools improving WIC retention (CFDA 93.307).

BMC customer concentration sits with federal health agencies and research funders. The National Institute on Drug Abuse leads with 76 awards, followed by the National Institute of Diabetes and Digestive and Kidney Diseases with 56 awards, and the National Institute of Allergy and Infectious Diseases with 43 awards. The CDC Pittsburgh dominates by potential value, anchoring $183.8 million across the CISA IDIQ and related immunization safety assessment work. The National Institute on Alcohol Abuse and Alcoholism accounts for $48.1 million across 24 awards, and the National Institute of Child Health and Human Development carries $42.3 million across 33 awards. These five agencies account for approximately 72% of combined potential value across BMC's award portfolio.

Activity has grown steadily: 53 awards in 2022 to 90 awards in 2025, with 67 awards recorded in 2026 through October. Fifty awards with ultimate completion dates in the next twenty-four months carry combined potential value of $1.2 million, creating near-term recompete exposure. SCI-reported federal service contract invoicing totaled $1.6 million in FY2022, declined to zero in FY2023, and recovered to $635 thousand in FY2025 across approximately 2 FTEs. On SCI-reportable service contracts, government-paid hourly rates ranged from a 10th percentile of $53.46/hr to a median of $143.56/hr, with senior clinical and research labor pricing reaching $1,192.94/hr at the 90th percentile.

BMC operates as a prime on 551 awards (67% of total activity) and as a subcontractor on 274 awards (33%), indicating substantial independent federal capacity. As a subcontractor, BMC delivers clinical and research services to prime research organizations including Georgia State University (racism and prenatal health disparities research), Johns Hopkins University (autism longitudinal research and kidney disease omics), Columbia University (HIV envelope research and amyloidosis in transthyretin cardiac amyloidosis), and Duke University (community paramedic and overdose response services). The organization functions as a leading clinical research and biomedical investigation site for large university-led consortia and national research networks, particularly within opioid use disorder, HIV, infectious disease, and chronic kidney disease research domains. No significant sub-hours engagement appears in SCI data, consistent with BMC's role as a clinical research institution that performs work with its own staff rather than subcontracting labor.